Hepatitis B News and Research

Latest Hepatitis B News and Research

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. Louis have shown.

8 Mar 2013

Study shows community-based HIV-prevention efforts increase testing rates, reduce HIV incidence

In Africa and Thailand, communities that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study presented this week at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

6 Mar 2013

HIV might promote aging and disease progression in people with HCV, study results suggest

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus, co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

5 Mar 2013

Express Scripts finds decline in 2012 U.S. spending on traditional prescription drugs

For the first time in more than 20 years, there was a decrease in 2012 U.S. spending on traditional prescription drugs — primarily pills people take to treat more common diseases such as high cholesterol and high blood pressure — according to new data released today by Express Scripts.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

HIV infection may increase risk of acute myocardial infarction

A study that analyzed data from more than 82,000 veterans suggests that infection with the human immunodeficiency virus (HIV) was associated with an increased risk of acute myocardial infarction (AMI, heart attack) beyond what is explained by recognized risk factors, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

4 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

Stem cell line could also advance research into liver cancers, cystic fibrosis

Chronic or acute, liver failure can be deadly. Toxins take over, the skin turns yellow and higher brain function slows. "There is no effective therapy at the moment to deal with the toxins that build up in your body," said Neil Talbot, a Research Animal Scientist for the USDA Agricultural Research Service. "Their only option now is to transplant a liver."

1 Mar 2013

State roundup: Health care industry calls drug testing bill in N.H. 'vague'

Representatives from the health care industry said Tuesday they have a vested interest in stopping employees from stealing controlled substances but a bill being considered by New Hampshire lawmakers to drug test their workers is too vague. The proposal is part of the legislative response to a recent scandal at Exeter Hospital, where an employee allegedly stole drugs and replaced them with Hepatitis C infected syringes later used on patients.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Govs brace for impact of scheduled cuts in home states

The nation's governors met in Washington over the weekend, and among their hottest topics: a White House warning regarding the state-by-state impact of sequestration, which is scheduled to kick in March 1.

26 Feb 2013

Wnt-induced Lgr5 expression marks stem cell production in the liver

For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions. But no lab in the world has been successful in identifying and growing liver stem cells in culture -- using any available technique - until now.

26 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

EASL unveils new publication - The burden of liver disease in Europe

Major progress has been made in the past 30 years in the knowledge and management of liver disease, yet approximately 29 million Europeans still suffer from a chronic liver condition. The European Association for the Study of the Liver (EASL) today unveiled its new publication The burden of liver disease in Europe: a review of available epidemiological data.

22 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Gilead to resolve Viread patent litigation case with Teva

Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

20 Feb 2013

Hepatitis B News and Research

Latest Hepatitis B News and Research

Melittin-loaded nanoparticles can destroy human immunodeficiency virus

Study shows community-based HIV-prevention efforts increase testing rates, reduce HIV incidence

HIV might promote aging and disease progression in people with HCV, study results suggest

Express Scripts finds decline in 2012 U.S. spending on traditional prescription drugs

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HIV infection may increase risk of acute myocardial infarction

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

Stem cell line could also advance research into liver cancers, cystic fibrosis

State roundup: Health care industry calls drug testing bill in N.H. 'vague'

EpiCept fourth quarter revenue decreases to $0.1 million

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Govs brace for impact of scheduled cuts in home states

Wnt-induced Lgr5 expression marks stem cell production in the liver

Janssen submits simeprevir regulatory application in Japan to treat HCV

EASL unveils new publication - The burden of liver disease in Europe

Daclatasvir has two primary modes of action against HCV

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Study may help design better DAA drug cocktails to treat HCV

Gilead to resolve Viread patent litigation case with Teva

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in